VEGFA and neoplasm: AP in cancer, sustaining immunosuppressive cell types and thus the release of cytokines and immune modulatory factors, such as VEGF, IL6, IL10, and TGFβ, and activating survival pathways, inhibits immunosurveillance and enhances tumor survival, metastasis and therapy resistance [115].